Biogen Idec ($BIIB) has shipped its application to the FDA for approval of an experimental therapy for the rare bleeding disorder hemophilia B. And the long-lasting clotting factor is the most advance…
WESTON, Mass. (BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the ma…
Biogen Idec's ALS drug binned after failed trial…
Weston, Mass.-based Biogen Idec has decided to discontinue development of dexpramipexole in amyotrophic lateral sclerosis (ALS), after top-line results of EMPOWER, its phase III trial, did not meet it…
